Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A realâ•'world investigation
![Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse - ScienceDirect Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0165572820303593-ga1.jpg)
Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse - ScienceDirect
Kappa Index versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders
![A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay](https://www.oatext.com/img/HMO-4-195-g001.gif)
A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay
Diagnostic and Prognostic Value of the Cerebrospinal Fluid Concentration of Immunoglobulin Free Light Chains in Clinically Isolated Syndrome with Conversion to Multiple Sclerosis | PLOS ONE
![Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity | SpringerLink Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10354-022-00912-7/MediaObjects/10354_2022_912_Fig1_HTML.png)
Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity | SpringerLink
![A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay](https://www.oatext.com/img/HMO-4-195-g002.gif)